XERIS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Prepaid Expense
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Increase (Decrease) in Prepaid Expense of $4.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was $4.49M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was -$145.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was -$1.25M, a 502.89% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was $5.15M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in prepaid expense for fiscal 2025 was $2.10M, a 25.34% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in prepaid expense for fiscal 2024 was $1.67M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in prepaid expense for fiscal 2023 was -$3.21M, a 182.48% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in prepaid expense for fiscal 2022 was $3.89M.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.34M 10-Q · filed 2026-08-06 | $3.09M derived: sum of 3 quarters · filed 2026-08-06 | $8.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$145.00K 10-Q · filed 2026-05-07 | -$1.40M derived: sum of 2 quarters · filed 2026-05-07 | $3.75M derived: sum of 3 quarters · filed 2026-05-07 | $3.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.90M derived: sum of 2 quarters · filed 2026-03-02 | $3.63M derived: sum of 3 quarters · filed 2026-08-06 | $2.10M 10-K · filed 2026-03-02 |
| 2025-09-30 | $5.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.88M derived: sum of 2 quarters · filed 2026-08-06 | $3.35M 10-Q · filed 2025-11-06 | $3.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$270.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.80M 10-Q · filed 2026-08-06 | -$1.49M derived: sum of 3 quarters · filed 2026-08-06 | -$1.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.53M 10-Q · filed 2026-05-07 | -$1.22M derived: sum of 2 quarters · filed 2026-05-07 | -$1.44M derived: sum of 3 quarters · filed 2026-05-07 | -$1.72M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $311.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $96.00K derived: sum of 2 quarters · filed 2026-03-02 | -$185.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.67M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$496.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.36M 10-Q · filed 2025-11-06 | -$674.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$281.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.58M 10-Q · filed 2025-08-07 | -$459.00K derived: sum of 3 quarters · filed 2026-03-02 | -$802.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $1.86M 10-Q · filed 2025-05-08 | -$178.00K derived: sum of 2 quarters · filed 2026-03-02 | -$521.00K derived: sum of 3 quarters · filed 2026-03-02 | -$2.57M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$2.38M derived: sum of 2 quarters · filed 2026-03-02 | -$4.43M derived: sum of 3 quarters · filed 2026-03-02 | -$3.21M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$343.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$2.40M derived: sum of 2 quarters · filed 2024-11-08 | -$1.17M 10-Q · filed 2024-11-08 | -$41.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$827.00K 10-Q · filed 2024-08-08 | $302.00K derived: sum of 3 quarters · filed 2025-03-06 | $2.14M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $1.23M 10-Q · filed 2024-05-09 | $2.35M derived: sum of 2 quarters · filed 2025-03-06 | $4.19M derived: sum of 3 quarters · filed 2025-03-06 | $5.05M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $2.97M derived: sum of 2 quarters · filed 2025-03-06 | $3.83M derived: sum of 3 quarters · filed 2025-03-06 | $3.89M 10-K · filed 2025-03-06 |
| 2022-09-30 | $1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.70M derived: sum of 2 quarters · filed 2023-11-09 | $2.76M 10-Q · filed 2023-11-09 | -$918.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $863.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $921.00K 10-Q · filed 2023-08-08 | -$2.75M derived: sum of 3 quarters · filed 2024-03-06 | -$1.43M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $58.00K 10-Q · filed 2023-05-09 | -$3.62M derived: sum of 2 quarters · filed 2024-03-06 | -$2.29M derived: sum of 3 quarters · filed 2024-03-06 | -$3.25M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$2.35M derived: sum of 2 quarters · filed 2024-03-06 | -$3.31M derived: sum of 3 quarters · filed 2024-03-06 | -$3.29M 10-K · filed 2024-03-06 |
| 2021-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $371.00K derived: sum of 2 quarters · filed 2022-11-09 | $386.00K 10-Q · filed 2022-11-09 | $640.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$957.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$942.00K 10-Q · filed 2022-08-10 | -$688.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $15.00K 10-Q · filed 2022-05-11 | $269.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$925.00K 10-K · filed 2022-03-11 | ||
| 2020-09-30 | -$1.18M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |